-
Mashup Score: 0Program Guide – ASCO Meeting Program Guide - 2 year(s) ago
AuthorsShaji KumarDepartment of Hematology, Mayo Clinic Rochester, Rochester, MNShaji Kumar, Zihan Wei, Michael A. Thompson, Bradley Snyder, Matthias Weiss, Lynne I. Wagner, Lale Kostakoglu, S. Vincent RajkumarOrganizationsDepartment of Hematology, Mayo Clinic Rochester, Rochester, MN, Dana-Farber Cancer Institute, Boston, MA, Aurora Cancer Care, Advocate Aurora Health, Milwaukee, WI, Brown…
Source: meetings.asco.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1Program Guide – ASCO Meeting Program Guide - 2 year(s) ago
AuthorsMohamed HendawiAurora Cancer Care, Advocate Aurora Health, Milwaukee, WIMohamed Hendawi, Luke Peterson, Eyob ale Tadesse, Frank M. Wolf, Thomas D. Brown, Michael A. ThompsonOrganizationsAurora Cancer Care, Advocate Aurora Health, Milwaukee, WI, Syapse INC, San Francisco, CA, Syapse, San Francisco, CAAbstract DisclosuresResearch FundingNo funding receivedNone Background: Patients (pts)…
Source: meetings.asco.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
Myocarditis as a rare, yet serious adverse event associated w/ immune checkpoint inhibitors in patients w/ NSCLC: Case series from a large community-based cancer center - Hendawi et al. @Aurora_Cancer #ASCO21 Abs e21047 https://t.co/OFrRxoxrt6 #irAE #ImmunoOnc #CardioOnc
-
-
Mashup Score: 3Program Guide – ASCO Meeting Program Guide - 2 year(s) ago
AuthorsMohamed HendawiAurora Cancer Care, Advocate Aurora Health, Milwaukee, WIMohamed Hendawi, Luke Peterson, Eyob ale Tadesse, Frank M. Wolf, Thomas D. Brown, Michael A. ThompsonOrganizationsAurora Cancer Care, Advocate Aurora Health, Milwaukee, WI, Syapse INC, San Francisco, CA, Syapse, San Francisco, CAAbstract DisclosuresResearch FundingNo funding receivedNone Background: Patients (pts)…
Source: meetings.asco.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
Myocarditis as a rare, yet serious adverse event associated w/ immune checkpoint inhibitors in patients w/ NSCLC: Case series from a large community-based cancer center - Hendawi et al. @Aurora_Cancer @Syapse #ASCO21 Abs e21047 https://t.co/OFrRxoxrt6 #irAE #ImmunoOnc #CardioOnc
-
-
Mashup Score: 1Leveraging machine learning technology to efficiently identify and match patients for precision oncology clinical trials. - 2 year(s) ago
e13588 Background: Pre-screening for clinical trials is becoming more challenging as inclusion/exclusion criteria becomes increasingly complex. Oncology precision medicine provides an exciting opportunity to simplify this process and quickly match patients with trials by leveraging machine learning technology. The Tempus TIME Trial site network matches patients to relevant, open, and recruiting…
Source: Journal of Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Leveraging machine learning technology to efficiently identify and match patients for precision oncology clinical trials [May 28, 2021] Sachse et al. #ASCO21 Abstract e13588 https://t.co/EpwreOCLny #PrecisionMedicine #ClinicalTrials #ctsm https://t.co/3da8JnhpUE
-
-
Mashup Score: 1Leveraging machine learning technology to efficiently identify and match patients for precision oncology clinical trials. - 2 year(s) ago
e13588 Background: Pre-screening for clinical trials is becoming more challenging as inclusion/exclusion criteria becomes increasingly complex. Oncology precision medicine provides an exciting opportunity to simplify this process and quickly match patients with trials by leveraging machine learning technology. The Tempus TIME Trial site network matches patients to relevant, open, and recruiting…
Source: Journal of Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Leveraging machine learning technology to efficiently identify and match patients for precision oncology clinical trials [May 28, 2021] Sachse et al. #ASCO21 Abstract e13588 https://t.co/EpwreOCLny #PrecisionMedicine #ClinicalTrials #ctsm https://t.co/5PZNWRLGR0
-
-
Mashup Score: 0Leveraging machine learning technology to efficiently identify and match patients for precision oncology clinical trials. - 2 year(s) ago
e13588 Background: Pre-screening for clinical trials is becoming more challenging as inclusion/exclusion criteria becomes increasingly complex. Oncology precision medicine provides an exciting opportunity to simplify this process and quickly match patients with trials by leveraging machine learning technology. The Tempus TIME Trial site network matches patients to relevant, open, and recruiting…
Source: Journal of Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Leveraging machine learning technology to efficiently identify and match patients for precision oncology clinical trials [May 28, 2021] Sachse et al. #ASCO21 Abstract e13588 https://t.co/EpwreOCLny #PrecisionMedicine #ClinicalTrials #ctsm https://t.co/Fc9C0y9jtx
-
-
Mashup Score: 0Program Guide – ASCO Meeting Program Guide - 2 year(s) ago
AuthorsEyob ale TadesseAurora Cancer Care, Advocate Aurora Health, Milwaukee, WIEyob ale Tadesse, Kayla Heslin, Mohamed Hendawi, Luke Peterson, Frank M. Wolf, Thomas D. Brown, Michael A. ThompsonOrganizationsAurora Cancer Care, Advocate Aurora Health, Milwaukee, WI, Advocate Aurora Health, Milwaukee, WI, Syapse INC, San Francisco, CA, Syapse, San Francisco, CAAbstract DisclosuresResearch…
Source: meetings.asco.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
Genomic markers associated with hyperprogression in patients with lung cancer treated with immune checkpoint inhibitors - Tadesse et al. #ASCO21 Abs 9105 https://t.co/IpuygzczQA #PrecisionMedicine #ImmunoOnc https://t.co/dpuyFLfsti
-
-
Mashup Score: 1Leveraging machine learning technology to efficiently identify and match patients for precision oncology clinical trials. - 2 year(s) ago
e13588 Background: Pre-screening for clinical trials is becoming more challenging as inclusion/exclusion criteria becomes increasingly complex. Oncology precision medicine provides an exciting opportunity to simplify this process and quickly match patients with trials by leveraging machine learning technology. The Tempus TIME Trial site network matches patients to relevant, open, and recruiting…
Source: Journal of Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Leveraging machine learning technology to efficiently identify and match patients for precision oncology clinical trials [May 28, 2021] Sachse et al. #ASCO21 Abstract e13588 https://t.co/EpwreOUUBG #PrecisionMedicine #ClinicalTrials #ctsm https://t.co/NCNOH2TV33
-
-
Mashup Score: 1Leveraging machine learning technology to efficiently identify and match patients for precision oncology clinical trials. - 2 year(s) ago
e13588 Background: Pre-screening for clinical trials is becoming more challenging as inclusion/exclusion criteria becomes increasingly complex. Oncology precision medicine provides an exciting opportunity to simplify this process and quickly match patients with trials by leveraging machine learning technology. The Tempus TIME Trial site network matches patients to relevant, open, and recruiting…
Source: Journal of Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Leveraging machine learning technology to efficiently identify and match patients for precision oncology clinical trials [May 28, 2021] Sachse et al. #ASCO21 Abstract e13588 https://t.co/EpwreOUUBG #PrecisionMedicine #ClinicalTrials #ctsm https://t.co/YoFr0fKPGi
-
-
Mashup Score: 1Leveraging machine learning technology to efficiently identify and match patients for precision oncology clinical trials. - 2 year(s) ago
e13588 Background: Pre-screening for clinical trials is becoming more challenging as inclusion/exclusion criteria becomes increasingly complex. Oncology precision medicine provides an exciting opportunity to simplify this process and quickly match patients with trials by leveraging machine learning technology. The Tempus TIME Trial site network matches patients to relevant, open, and recruiting…
Source: Journal of Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Leveraging machine learning technology to efficiently identify and match patients for precision oncology clinical trials [May 28, 2021] Sachse et al. #ASCO21 Abstract e13588 https://t.co/EpwreOUmM8 #PrecisionMedicine #ClinicalTrials #ctsm https://t.co/OO4m10kOqY
-
#EAonc ECOG-ACRIN EAA181: Effective quadruplet utilization after treatment evaluation (EQUATE) - a Ph3 RCT for newly diagnosed multiple myeloma (NDMM) not intended for early autologous SCT - @myelomaMD et al. @VincentRK #ASCO21 Abs TPS8052 https://t.co/iLQt2usOz5 #mmsm